FRX Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Fennec Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 9.81 CAD 10.6% Market Closed

Market Cap: CA$268m

F	Fennec Pharmaceuticals Inc TSX:FRX	US
P	Pernod Ricard SA XETRA:PER	FR

Profitability Summary

Fennec Pharmaceuticals Inc's profitability score is 36/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

92%

Strong 3Y Average Gross Margin

93%

Declining Gross Margin

94% > 92%

Negative Operating Margin

-14%

Negative 3Y Average Operating Margin

-114%

Operating Margin is Increasing

-755% > -14%

Negative Net Margin

-22%

Negative 3Y Average Net Margin

-130%

Net Margin is Increasing

-810% > -22%

Negative Free Cash Flow Margin

-28%

Negative 3Y Average Free Cash Flow Margin

-93%

Free Cash Flow Margin is Increasing

-645% > -28%

Negative ROE

-66%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-3 918%

ROIC is Increasing

-32 427% > -29%

View All

Hide

Collapse

36 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.